U.S. Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection {Intramuscular, Subcutaneous, and Intravenous}), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Forecast, 2023-2030

Last Updated: December 01, 2025 | Format: PDF | Report ID: FBI107918

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Multiple Sclerosis - For Key Countries
2. Regulatory Scenario - For Key Countries
3. Patent Snapshot, Key Players
4. New Product Launches
5. Pipeline Analysis & R&D Investments
6. Key Industry Developments - Mergers, Acquisitions and Partnerships
7. Impact of COVID-19 on the Market
U.S. Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2019-2030
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Immunomodulators
  2. Immunosuppressants
  3. Interferons
  4. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Injection
    1. Intramuscular
    2. Subcutaneous
    3. Intravenous
3. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
Competitive Analysis
1. U.S. Market Share Analysis
2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  1. Biogen
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  2. Teva Pharmaceutical Industries Ltd.
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  3. Merck KGaA
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  4. Sanofi
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  5. Novartis AG
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  6. F. Hoffmann-La Roche Ltd.
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  7. Pfizer Inc.
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  9. Bristol-Myers Squibb Company
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Multiple Sclerosis - For Key Countries
2. Regulatory Scenario - For Key Countries
3. Patent Snapshot, Key Players
4. New Product Launches
5. Pipeline Analysis & R&D Investments
6. Key Industry Developments - Mergers, Acquisitions and Partnerships
7. Impact of COVID-19 on the Market
U.S. Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2019-2030
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Immunomodulators
  2. Immunosuppressants
  3. Interferons
  4. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Injection
    1. Intramuscular
    2. Subcutaneous
    3. Intravenous
3. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
Competitive Analysis
1. U.S. Market Share Analysis
2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  1. Biogen
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  2. Teva Pharmaceutical Industries Ltd.
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  3. Merck KGaA
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  4. Sanofi
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  5. Novartis AG
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  6. F. Hoffmann-La Roche Ltd.
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  7. Pfizer Inc.
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  9. Bristol-Myers Squibb Company
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)

Read Less

List of Figures

Figure 1: U.S. Multiple Sclerosis Drugs Market Revenue Breakdown (USD Billion, %) by Drug Class, 2022 & 2030

Figure 2: U.S. Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2022 & 2030

Figure 3: U.S. Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2022 & 2030

Figure 4: U.S. Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2022 & 2030

Figure 5: U.S. Multiple Sclerosis Drugs Market Share (%), By Company

List of Tables

Table 1: U.S. Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Drug Class, 2019–2030

Table 2: U.S. Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Route of Administration, 2019–2030

Table 3: U.S. Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Injection, 2019–2030

Table 4: U.S. Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Distribution Channel, 2019–2030

STUDY PERIOD: 2019-2030
BASE YEAR: 2022
HISTORICAL DATA: 2019-2021
NO OF PAGES: 110

Buy Now

Download Free Sample

Security Code

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

+91 744 740 1245 (APAC)
sales@fortunebusinessinsights.com